vs
Apellis Pharmaceuticals, Inc.（APLS）与8X8 INC（EGHT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是8X8 INC的1.1倍（$199.9M vs $185.1M），8X8 INC净利率更高（2.8% vs -29.5%，领先32.2%），8X8 INC同比增速更快（3.4% vs -5.9%），8X8 INC自由现金流更多（$19.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
8x8 Inc是源自美国的企业级云通信与客户体验软件服务商，依托云架构为企业提供统一通信、呼叫中心及通信平台即服务（CPaaS）等产品方案，公司总部位于加利福尼亚州坎贝尔，其股票在纳斯达克交易所挂牌交易。
APLS vs EGHT — 直观对比
营收规模更大
APLS
是对方的1.1倍
$185.1M
营收增速更快
EGHT
高出9.4%
-5.9%
净利率更高
EGHT
高出32.2%
-29.5%
自由现金流更多
EGHT
多$33.4M
$-14.3M
两年增速更快
APLS
近两年复合增速
1.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $185.1M |
| 净利润 | $-59.0M | $5.1M |
| 毛利率 | — | 63.9% |
| 营业利润率 | -25.6% | 5.2% |
| 净利率 | -29.5% | 2.8% |
| 营收同比 | -5.9% | 3.4% |
| 净利润同比 | -62.2% | 68.4% |
| 每股收益（稀释后） | $-0.40 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEGHT
| Q4 25 | $199.9M | $185.1M | ||
| Q3 25 | $458.6M | $184.1M | ||
| Q2 25 | $178.5M | $181.4M | ||
| Q1 25 | $166.8M | $177.0M | ||
| Q4 24 | $212.5M | $178.9M | ||
| Q3 24 | $196.8M | $181.0M | ||
| Q2 24 | $199.7M | $178.1M | ||
| Q1 24 | $172.3M | $179.4M |
净利润APLSEGHT
| Q4 25 | $-59.0M | $5.1M | ||
| Q3 25 | $215.7M | $767.0K | ||
| Q2 25 | $-42.2M | $-4.3M | ||
| Q1 25 | $-92.2M | $-5.4M | ||
| Q4 24 | $-36.4M | $3.0M | ||
| Q3 24 | $-57.4M | $-14.5M | ||
| Q2 24 | $-37.7M | $-10.3M | ||
| Q1 24 | $-66.4M | $-23.6M |
毛利率APLSEGHT
| Q4 25 | — | 63.9% | ||
| Q3 25 | — | 64.8% | ||
| Q2 25 | — | 66.4% | ||
| Q1 25 | — | 67.8% | ||
| Q4 24 | — | 67.7% | ||
| Q3 24 | — | 68.1% | ||
| Q2 24 | — | 67.9% | ||
| Q1 24 | — | 68.2% |
营业利润率APLSEGHT
| Q4 25 | -25.6% | 5.2% | ||
| Q3 25 | 48.7% | 2.9% | ||
| Q2 25 | -18.6% | 0.3% | ||
| Q1 25 | -50.0% | 0.2% | ||
| Q4 24 | -12.3% | 5.0% | ||
| Q3 24 | -24.0% | 4.0% | ||
| Q2 24 | -14.7% | -0.8% | ||
| Q1 24 | -36.0% | -7.9% |
净利率APLSEGHT
| Q4 25 | -29.5% | 2.8% | ||
| Q3 25 | 47.0% | 0.4% | ||
| Q2 25 | -23.6% | -2.4% | ||
| Q1 25 | -55.3% | -3.1% | ||
| Q4 24 | -17.1% | 1.7% | ||
| Q3 24 | -29.2% | -8.0% | ||
| Q2 24 | -18.9% | -5.8% | ||
| Q1 24 | -38.5% | -13.1% |
每股收益（稀释后）APLSEGHT
| Q4 25 | $-0.40 | $0.04 | ||
| Q3 25 | $1.67 | $0.01 | ||
| Q2 25 | $-0.33 | $-0.03 | ||
| Q1 25 | $-0.74 | $-0.04 | ||
| Q4 24 | $-0.30 | $0.02 | ||
| Q3 24 | $-0.46 | $-0.11 | ||
| Q2 24 | $-0.30 | $-0.08 | ||
| Q1 24 | $-0.54 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $86.9M |
| 总债务越低越好 | — | $321.2M |
| 股东权益账面价值 | $370.1M | $142.9M |
| 总资产 | $1.1B | $661.5M |
| 负债/权益比越低杠杆越低 | — | 2.25× |
8季度趋势，按日历期对齐
现金及短期投资APLSEGHT
| Q4 25 | $466.2M | $86.9M | ||
| Q3 25 | $479.2M | $75.9M | ||
| Q2 25 | $370.0M | $81.3M | ||
| Q1 25 | $358.4M | $88.0M | ||
| Q4 24 | $411.3M | $104.2M | ||
| Q3 24 | $396.9M | $117.4M | ||
| Q2 24 | $360.1M | $130.8M | ||
| Q1 24 | $325.9M | $117.3M |
总债务APLSEGHT
| Q4 25 | — | $321.2M | ||
| Q3 25 | — | $325.8M | ||
| Q2 25 | — | $335.4M | ||
| Q1 25 | — | $350.0M | ||
| Q4 24 | — | $364.5M | ||
| Q3 24 | — | $396.9M | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | $409.7M |
股东权益APLSEGHT
| Q4 25 | $370.1M | $142.9M | ||
| Q3 25 | $401.2M | $133.2M | ||
| Q2 25 | $156.3M | $128.2M | ||
| Q1 25 | $164.2M | $122.2M | ||
| Q4 24 | $228.5M | $113.0M | ||
| Q3 24 | $237.1M | $109.8M | ||
| Q2 24 | $264.3M | $104.6M | ||
| Q1 24 | $266.7M | $102.0M |
总资产APLSEGHT
| Q4 25 | $1.1B | $661.5M | ||
| Q3 25 | $1.1B | $670.8M | ||
| Q2 25 | $821.4M | $684.3M | ||
| Q1 25 | $807.3M | $683.2M | ||
| Q4 24 | $885.1M | $698.2M | ||
| Q3 24 | $901.9M | $740.1M | ||
| Q2 24 | $904.5M | $755.7M | ||
| Q1 24 | $831.9M | $756.0M |
负债/权益比APLSEGHT
| Q4 25 | — | 2.25× | ||
| Q3 25 | — | 2.45× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | — | 2.86× | ||
| Q4 24 | — | 3.23× | ||
| Q3 24 | — | 3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | 4.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $20.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $19.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 10.3% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 4.07× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $43.8M |
8季度趋势，按日历期对齐
经营现金流APLSEGHT
| Q4 25 | $-14.2M | $20.7M | ||
| Q3 25 | $108.5M | $8.8M | ||
| Q2 25 | $4.4M | $11.9M | ||
| Q1 25 | $-53.4M | $5.9M | ||
| Q4 24 | $19.4M | $27.2M | ||
| Q3 24 | $34.1M | $12.3M | ||
| Q2 24 | $-8.3M | $18.1M | ||
| Q1 24 | $-133.0M | $12.7M |
自由现金流APLSEGHT
| Q4 25 | $-14.3M | $19.1M | ||
| Q3 25 | $108.3M | $7.7M | ||
| Q2 25 | $4.4M | $11.5M | ||
| Q1 25 | $-53.4M | $5.5M | ||
| Q4 24 | $19.3M | $26.8M | ||
| Q3 24 | — | $11.1M | ||
| Q2 24 | $-8.4M | $17.8M | ||
| Q1 24 | $-133.3M | $12.3M |
自由现金流率APLSEGHT
| Q4 25 | -7.1% | 10.3% | ||
| Q3 25 | 23.6% | 4.2% | ||
| Q2 25 | 2.5% | 6.3% | ||
| Q1 25 | -32.0% | 3.1% | ||
| Q4 24 | 9.1% | 15.0% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | -4.2% | 10.0% | ||
| Q1 24 | -77.3% | 6.9% |
资本支出强度APLSEGHT
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.2% |
现金转化率APLSEGHT
| Q4 25 | — | 4.07× | ||
| Q3 25 | 0.50× | 11.52× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 9.01× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EGHT
| Services | $179.7M | 97% |
| Other | $5.4M | 3% |
